Open Outbreak

Lassa fever

Also known as: Lassa, Lassa virus, arenavirus, Lassa hemorrhagic fever, arenavirus (a broader virus group)

Lassa fever is an illness caused by Lassa virus, a virus carried mainly by multimammate rats in West Africa. People usually become infected through contact with infected rodents or food and household items contaminated by their urine or droppings. Infection can also pass between people through direct contact with blood or other body fluids, especially when healthcare infection-control measures are inadequate. There is no epidemiological evidence of airborne spread between people. About 80% of infections cause no symptoms or only mild illness. Severe illness can damage several organs and is especially dangerous during pregnancy. Hearing loss can follow recovery. WHO gives an overall fatality estimate of about 1%, but mortality is much higher among patients hospitalized with severe disease. Early supportive care, including careful fluid management and treatment of symptoms, improves survival. Ribavirin has been used, but its benefit remains uncertain. The retrieved WHO sources report no protective vaccine. Preventing rodent contamination, recognizing illness early and protecting healthcare workers are central to control.

Key facts

TransmissionPrimarily contact with infected rodents or food and household items contaminated with rodent urine or faeces; less commonly direct contact with an infected person's blood or other body fluids, including through contaminated medical equipment. No epidemiological evidence supports airborne spread between humans.
Incubation2–21 days, according to the WHO fact sheet.
Case fatalityWHO estimates about 1% overall and 15% or higher among patients hospitalized with severe disease. Nigeria reported 17% among confirmed cases through 2023-04-16. Reliable separate estimates with and without treatment are unknown from the retrieved sources.
Reproduction numberunknown
VaccineThe retrieved WHO outbreak notice, dated 2023-05-01, reports no vaccine that protects against Lassa fever; a later regulatory status was not established by the retrieved sources.
TreatmentEarly intensive supportive care, including fluid management and treatment of symptoms. WHO reports no approved antiviral drug; ribavirin has been used, but its efficacy remains uncertain.
ReservoirMainly Mastomys rodents, commonly called multimammate rats; other rodent species may also contribute.
Endemic regionsWest Africa. WHO lists Benin, Ghana, Guinea, Liberia, Mali, Nigeria and Sierra Leone as endemic; outbreaks or sporadic cases have also been reported in Burkina Faso, Côte d’Ivoire and Togo.

Transmission

Most infections begin with exposure to infected rodents. Multimammate rats can live around homes, food stores and fields. They shed Lassa virus in urine and droppings without becoming visibly ill. People can be exposed through contaminated food or household items, direct contact with rats, or dust contaminated by rodent waste. Spread between people is less common. It involves direct contact with blood or other body fluids, or contaminated medical equipment. Healthcare workers are at particular risk when infection-control precautions are missing. WHO finds no epidemiological evidence of airborne spread between people. Keeping food protected from rodents and maintaining safe healthcare practices address the main documented routes.

Symptoms and severity

Symptoms can begin 2–21 days after infection. About 80% of infections cause no symptoms or mild illness. Illness often starts gradually with fever, weakness and headache. Sore throat, muscle pain, vomiting, diarrhoea and abdominal pain may follow. Severe disease can cause organ damage, low blood pressure, bleeding, seizures or coma; bleeding is not required for severe illness. WHO estimates mortality at about 1% overall, compared with 15% or more among people hospitalized with severe disease. These figures describe different groups, not treatment effects. Pregnancy, particularly late pregnancy, carries greater danger. Hearing loss has been reported in up to 25% of recovered patients and is often permanent. Laboratory testing is needed because early symptoms resemble other infections.

Treatment and vaccines

Early intensive supportive care improves the chance of survival. This includes careful fluid management and treatment of specific symptoms and complications. WHO reports that there is no antiviral drug approved specifically for Lassa fever. Ribavirin has been used for decades, and an influential 1986 study reported benefit, but WHO now describes considerable uncertainty about its effect on patient outcomes. It should not be presented as a proven cure. The retrieved 2023 WHO outbreak notice reports no protective vaccine; the sources retrieved here do not establish a later approval. Prevention therefore relies on reducing rodent exposure, prompt diagnosis, appropriate patient isolation and reliable infection-control measures. Survivors may also need follow-up for hearing loss and other lasting problems.

Where it occurs

Lassa fever is primarily a West African disease. WHO identifies Benin, Ghana, Guinea, Liberia, Mali, Nigeria and Sierra Leone as countries where it is endemic, meaning infection occurs there regularly. WHO also records outbreaks or sporadic cases in Burkina Faso, Côte d’Ivoire and Togo, and says the disease probably exists in other West African countries. Rodent exposure around homes and food storage is an important part of its geography. In Nigeria, transmission occurs throughout the year, with larger seasonal outbreaks typically during the dry season from December to April. Notices from European countries show that cases can also be detected outside the endemic region. Such reports do not by themselves establish local, sustained transmission.

Recent history

Open Outbreak's archive contains 29 Lassa-related events, covering notices from 1996 onward. These are archive entries, not necessarily 29 separate confirmed outbreaks: some concern suspected cases, imported infections or an absence of disease. The returned WHO notices include Guinea, Togo and the United Kingdom in 2022, followed by Nigeria on 2023-05-01. For Nigeria, WHO reported 877 confirmed cases and 152 deaths through 2023-04-16, a confirmed-case fatality ratio of 17%. The 4,702 suspected cases were a separate category and should not be treated as confirmed infections. WHO assessed regional and global risk as low for that outbreak. As of this page's reference date, 2026-11-15, the retrieved notices do not establish the current Nigerian case total or outbreak trend.

What to watch

Important warning signals include confirmed infections in new regions, repeated local transmission outside known endemic areas, and clusters linked to healthcare or direct contact with patients. Human-to-human spread already occurs, so the concern would be a rise in such spread, not its first appearance. Infections among healthcare workers can flag problems with recognition, protective measures or equipment safety. Delays in testing, shortages of isolation space and reduced access to supportive care can worsen an outbreak response. WHO has identified these pressures in past outbreaks. Treatment and vaccine announcements also need scrutiny: robust clinical evidence and regulatory approval matter more than promising early results. The retrieved sources do not establish antiviral resistance as a current driver or document a protective vaccine supply.

Related outbreaks

Updated